Faron Pharmaceuticals

2,46

EUR

+2,07 %

5 171 följer bolaget

FARON

First North Finland

Bioteknik & Läkemedel

Hälsovård

Overview

Financials & Estimates

Investor consensus

+2,07%

+20,88%

−3,15%

+16,04%

−5,93%

+44,2%

−9,56%

−54,1%

−29,31%

Faron Pharmaceuticals är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som dominerande kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.

Börsvärde

274,54 mn EUR

Omsatt (värde)

280,7 tn EUR

P/E (just.) (25e)

−13,47

EV/EBIT (adj.) (25e)

−15,2

P/B (25e)

−15,12

EV/S (25e)

71 752,13

Direktavkastnings- % (25e)

-

Coverage

Rekommendation

Öka

Riktkurs

2.80 EUR

Uppdaterad

2025-02-28

Antti Siltanen

Analytiker

Senaste analysen

Latest analysis report

Released: 2025-02-28

Latest extensive report

Released: 2022-08-23

Omsättning & EBIT-%

Omsättning mn

EBIT-%

Vinst per aktie & Utdelning

EPS (adj.)

Direktavkastning

Finansiell kalender

27/8

2025

Delårsrapport Q2'25

Risk

Business risk

Valuation risk

Låg

Hög

Alla

Analys

Webcasts

Pressmeddelanden

VisarAlla typer av innehåll

Regulatoriskt pressmeddelande2025-03-21 13:15

Board Changes

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-03-21 11:45

Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM

Faron Pharmaceuticals

Pressmeddelande2025-03-21 06:17

Carnegie Access: Faron Pharmaceuticals: Cancer meets a clever opponent

Faron Pharmaceuticals

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

Inderes användarkonto

Ger dig möjlighet att följa bolag och beställa notifikationer

Tillgång till analytikerkommentarer och rekommendationer

Tillgång till vårt aktiescreeningsverktyg och andra populära verktyg

Skapa användarkonto

Regulatoriskt pressmeddelande2025-03-20 07:00

Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected

Faron Pharmaceuticals

Analytikerkommentar2025-03-04 06:29 av

Orphan drug status for Faron in the US

This status offers Faron certain benefits for the development and commercialization of bexmarilimab.

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-03-03 12:00

Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-02-28 12:00

NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING

Faron Pharmaceuticals

Faron H2'24: Towards April readout

Aktieanalys2025-02-28 07:40 av

Faron H2'24: Towards April readout

Patient enrollment in the BEXMAB study was completed in January after the period had ended, and future highlights include the planned readouts in April.

Faron Pharmaceuticals

Pressmeddelande2025-02-27 15:22

Redeye: Faron Pharmaceuticals H2 - En route to pivotal studies

Faron Pharmaceuticals

Faron, Webcast, Q4'24

Webcast2025-02-27 09:00

Faron, Webcast, Q4'24

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-02-27 07:30

Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS)

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-02-27 07:15

Faron Pharmaceuticals Ltd’s Annual Report 2024 published

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-02-27 07:00

Faron’s Financial Statement Release 1 January to 31 December 2024

Faron Pharmaceuticals

Faron H2'24 preview: BEXMAB results are maturing

Analytikerkommentar2025-02-26 07:43 av

Faron H2'24 preview: BEXMAB results are maturing

Faron updated its plans for the blood cancer study BEXMAB based on feedback from the FDA.

Faron Pharmaceuticals

Pressmeddelande2025-02-19 10:00

Faron Pharmaceuticals will publish its Financial Statement Release 2024 and Annual Report 2024 on Thursday 27 February 2025

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-02-14 12:00

Holding(s) in Company

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-02-11 07:30

Change of Broker

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-02-06 15:00

Holding(s) in Company

Faron Pharmaceuticals

Analytikerkommentar2025-02-06 08:06 av

As expected, Faron raised funding through a directed issue

Last night, Faron announced last night that he would carry out a targeted issue to be conducted by way of an accelerated book-building. The company was aiming for a capital raise of around 10 MEUR, but with a 1.8-fold oversubscription, the company will upsize the issue and raise gross proceeds of 12 MEUR (before expenses).

Faron Pharmaceuticals

Regulatoriskt pressmeddelande2025-02-06 07:00

Results of the Significantly Oversubscribed Placing

Faron Pharmaceuticals

Forum uppdateringar

Part 2 of the article series! Probabilities of success in drug development The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development. Drug development companies typically examine...

2024-09-26 13:37

by Jesper Hagman

2

A little news from Faron: On Wednesday, Faron Pharmaceuticals published new positive results from the BEXMAB study to examine the efficacy of the company’s precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. Faron also...

2023-07-23 18:02

by börsen84

2

Hello Antti! Thank you very much for your response and also for the excellent analyses! Without you, interpreting a company like this would be very difficult for me alone. The industry is so challenging for an ordinary investor like myself. You’re doing a great job, and I appreciate...

2023-05-20 16:31

by börsen84

2

Hi Börsen, Although a bit old, the video and our Initiation of Coverage report are mostly still relevant. The main developments since recording the vid have been the faster than expected development of the phase I/II BEXMAB trial investigating bexmarilimab for treatment of blood ...

2023-05-20 14:35

by Antti Siltanen

2

Faron received an Innovation Passport in the UK for the treatment of relapsed/refractory myelodysplastic syndrome (r/r MDS) and will initiate the BEXMAB trial, accelerating drug development and patient access to treatments. Inderes Progress for Faron in the UK - Inderes Faron announced...

2024-12-04 22:09

by börsen84

1

New series of articles! We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply...

2024-09-10 06:49

by Jesper Hagman

1

Aktiekursens samtidiga uppgång har emellertid försämrat förhållandet mellan avkastning och risk. Under det kommande året är en central drivkraft för aktieavkastningen resultaten från fas II av blodcancerstudien BEXMAB och finansiella lösningar, där Faron har hänvisat till pågående...

2023-12-24 21:16

by börsen84

1

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.